AI-generated analysis. Always verify with the original filing.
Agios Pharmaceuticals, Inc. announced fourth quarter and full year 2025 financial results, reporting PYRUKYND worldwide net revenues of $20.0 million in Q4 and $54.0 million for the year, AQVESME FDA approval for thalassemia with U.S. availability, and $1.2 billion in cash as of December 31, 2025.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On February 12, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter a
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued February 12 , 20 26 104 Cover Page Interactive Data File (emb
| Metric | Value | Basis |
|---|---|---|
| Net Product Revenue (U.S. PYRUKYND) | $16.00 | |
| Net Product Revenue (ex-U.S. PYRUKYND) | $4.00 | |
| Net Loss | $108.00 | |
| Cost of Sales | $1.90 | |
| Research and Development Expenses | $88.10 | |
| Selling, General and Administrative Expenses | $51.60 |